拉诺康唑(Lanoconazole) - 药物靶点：fungal CYP51A1_在研适应症：足癣，念珠菌病，癣_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lanoconazole (JP17/INN)、Latoconazole

+ [5]

靶点

fungal CYP51A1

作用机制

fungal CYP51A1抑制剂(真菌细胞色素P450家族成员51抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Nihon Nohyaku Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1994-07-01),

念珠菌病花斑癣癣

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C14H10ClN3S2

InChIKeyZRTQSJFIDWNVJW-WYMLVPIESA-N

CAS号101530-10-3

关联

9

项与拉诺康唑相关的临床试验

JPRN-UMIN000036939 / CompletedN/A

Clinical research about the change factors for amount of drug in stratum corneum(lanoconazole cream, solution) - Clinical research about the change factors for amount of drug in stratum corneum

开始日期2019-06-21

申办/合作机构

Maruho Co., Ltd.

JPRN-UMIN000029240 / CompletedN/AIIT

Dermato-pharmacokinetic study of single application of lanoconazole - Dermato-pharmacokinetic study of single application of lanoconazole

开始日期2017-10-02

申办/合作机构

Oita University

JPRN-UMIN000019856 / CompletedN/AIIT

Evaluation of dermato-pharmacokinetics after repeated application of lanoconazole -whole day application 5days repeated trial- - Evaluation of dermato-pharmacokinetics after repeated application of lanoconazole

开始日期2016-01-10

申办/合作机构-

100 项与拉诺康唑相关的临床结果

登录后查看更多信息

100 项与拉诺康唑相关的转化医学

登录后查看更多信息

100 项与拉诺康唑相关的专利（医药）

登录后查看更多信息

69

项与拉诺康唑相关的文献（医药）

2023-04-30·Journal of fungi (Basel, Switzerland)

High Diversity of Fusarium Species in Onychomycosis: Clinical Presentations, Molecular Identification, and Antifungal Susceptibility.

Article

作者: Fan, Yun-Chen ; Chuang, Ya-Hui ; Sun, Pei-Lun ; Hui, Rosaline Chung-Yee ; Lu, Lai-Ying ; Ou, Jie-Hao

Fusarium are uncommon but important pathogenic organisms; they cause non-dermatophyte mould (NDM) onychomycosis. Patients typically respond poorly to treatment owing to Fusarium's native resistance to multiple antifungal drugs. However, epidemiological data for Fusarium onychomycosis are lacking in Taiwan. We retrospectively reviewed the data of 84 patients with positive Fusarium nail sample cultures at Chang Gung Memorial Hospital, Linkou Branch between 2014 and 2020. We aimed to investigate the clinical presentations, microscopic and pathological characteristics, antifungal susceptibility, and species diversity of Fusarium in patients with Fusarium onychomycosis. We enrolled 29 patients using the six-parameter criteria for NDM onychomycosis to determine the clinical significance of Fusarium in these patients. All isolates were subjected to species identification by sequences and molecular phylogeny. A total of 47 Fusarium strains belonging to 13 species in four different Fusarium species complexes (with Fusarium keratoplasticum predominating) were isolated from 29 patients. Six types of histopathology findings were specific to Fusarium onychomycosis, which may be useful for differentiating dermatophytes from NDMs. The results of drug susceptibility testing showed high variation among species complexes, and efinaconazole, lanoconazole, and luliconazole showed excellent in vitro activity for the most part. This study's primary limitation was its single-centre retrospective design. Our study showed a high diversity of Fusarium species in diseased nails. Fusarium onychomycosis has clinical and pathological features distinct from those of dermatophyte onychomycosis. Thus, careful diagnosis and proper pathogen identification are essential in the management of NDM onychomycosis caused by Fusarium sp.

2023-03-01·Mycoses

In vitro antifungal susceptibility profile of Iranian Fusarium isolates: Emphasising on the potent inhibitory effect of efinaconazole compared to other drugs

Article

作者: Haghani, Iman ; Katiraee, Farzad ; Shokohi, Tahereh ; Kachuei, Reza ; Faeli, Leila ; Nazeri, Mehdi ; Javidnia, Javad ; Salimi, Maryam ; Hedayati, Mohammad Taghi ; Badali, Hamid ; M.S. Al Hatmi, Abdullah ; Abastabar, Mahdi ; Khodavaisy, Sadegh ; Aghili, Seyed Reza ; Nosratabadi, Mohsen ; Mohammadi, Rasoul ; Zarrinfar, Hossein ; Javan‐Nikkhah, Mohammad ; Najafzadeh, Mohammad‐Javad

AbstractBackgroundFusarium species are opportunistic human pathogens that remarkably cause fungal infections ranging from superficial to fatal invasive disseminated infections. Fusarium species are notoriously resistant to the majority of antifungal agents.ObjectivesTherefore, detailed studies regarding in vitro susceptibility are required and may lead to a better prognosis of severe infections.MethodsWe evaluated 25 antifungal drugs in vitro against 282 clinical and environmental Fusarium isolates.ResultsFusarium species demonstrated high MICs/MECs values to the most commonly used antifungal drugs in clinical practice. The geometric mean (GM) MICs for luliconazole (0.004 μg/ml) and lanoconazole (0.012 μg/ml) were the lowest, followed by efinaconazole (0.98 μg/ml) and amphotericin B (1.04 μg/ml).ConclusionsEfinaconazole, a novel triazole, may be a promising candidate for the treatment of superficial Fusarium infections. Furthermore, the development of systemic formulations of these drugs as well as further in vitro and in vivo investigations could aid in the treatment of systemic fusariosis.

2022-11-01·Mycoses

Prevalence, genetic diversity and antifungal susceptibility profiles of F. fujikuroi, F. solani and Fusarium incarnatum‐equiseti species complexes from onychomycosis in north of Iran

Article

作者: Shokohi, Tahereh ; Hedayati, Mohammad Taghi ; Haghani, Iman ; Dalimi Asl, Abdolhossein ; Shams‐Ghahfarokhi, Masoomeh

AbstractOnychomycosis, a nail fungal infection, is normally caused by dermatophytes. However, yeasts and non‐dermatophyte moulds (NDM) are among pathogens that cause nail disease. Regarding, this study aimed to describe the molecular epidemiology of Fusarium onychomycosis in the North of Iran. Two hundred and fifty seven nail samples collected from the patients clinically suspected of onychomycosis were subjected to direct microscopy, calcofluor white staining and culture. Fusarium isolates were identified at a species level through determination of multi‐locus sequences for internal transcribed spacer and translation elongation factor 1 alpha. Based on the findings, Fusarium species were isolated from onychomycosis patients (n = 27). According to a previous partial genes analysis, the species in the recent study belonged to the members of F. fujikuroi species complex (n = 14), Fusarium incarnatum‐equiseti species complex (n = 1) and F. solani species complex (n = 12). In this study, F. proliferatum was the dominant Fusarium species collected from the samples. The correct identification of Fusarium species is essential regarding the increased prevalence of Fusarium onychomycosis and the inherent resistance of these agents to a wide spectrum of antifungals. The obtained results indicated variation in the epidemiology of Fusarium species isolated from onychomycosis. Moreover, the minimum inhibitory concentration (MIC) of luliconazole and lanoconazole was in the range of 0.001–1 μg/ml, with the geometric mean of MICs obtained at 0.0103 and 0.0343 μg/ml against Fusarium species, respectively. These findings can increase researchers' knowledge regarding diversity of species, distribution of onychomycosis and the choice of a proper treatment.

100 项与拉诺康唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01092	-	D01A	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
足癣	日本	Nihon Nohyaku Co., Ltd.	2006-05-16
念珠菌病	日本	Maruho Co., Ltd.	1994-07-01
癣	日本	Maruho Co., Ltd.	1994-07-01
花斑癣	日本	Maruho Co., Ltd.	1994-07-01